The aim of the collaboration is to develop new drugs for neurodegenerative diseases

The aim of the collaboration is to develop new drugs for neurodegenerative diseases

The ALBORADA Drug Discovery Institute (ADDI) announced today (Tuesday, November 8) that it will collaborate with pharmaceutical company YD Global Life Science (YDGLS) to develop inhibitors of the unfolded protein response for the treatment of diseases that cause dementia.

Based at the University of Cambridge, ADDI is part of Alzheimer’s Research UK’s Drug Discovery Alliance, which aims to develop new medicines for neurodegenerative diseases. The ADDI is funded by a donation to Alzheimer’s Research UK from the ALBORADA Trust, a charitable foundation founded by philanthropist Kirsten Rausing.

Neuroscience eBook

Compilation of the top interviews, articles and news from the last year. Download a free copy

ADDI has developed modulators of the protein eIF2B. These modulators are capable of inhibiting the unfolded protein response, a mechanism that researchers believe causes neurodegeneration when chronically activated in the brain.

As part of the collaboration, ADDI, YDGLS and subsidiary SapiensBio will work together to further develop the existing modulators discovered at the University of Cambridge and also develop new chemical leads.

They will apply innovative approaches in medicinal chemistry, structural biology and machine learning to develop further modulators and identify a molecule ready for clinical development.

“This collaboration will help build on the ALBORADA Drug Discovery Institute’s exciting drug discovery program,” said Dr. John Skidmore, Chief Scientific Officer of ADDI. "Our chemistry is very promising and we are excited to draw on YDGLS' expertise to further advance our work toward the clinic. The partnership will also benefit from SapiensBio's proprietary technologies to develop additional chemical leads against this important drug target."

We are very pleased to participate in the cooperation program with the ALBORADA Drug Discovery Institute, which has excellent experience in drug discovery against neurodegenerative diseases. We believe that YDGLS’ capabilities in chemistry and biology will complement theADDI’s valuable expertise.”

Dr. Sihyeon An, Managing Director, YDGLS

“We look forward to collaborating with the ADDI team and applying Sapientia, SapiensBio’s data-driven and machine learning-enabled workflow, to find new medicines to combat neurodegenerative diseases,” commented Dr. Incheol Ryu, CEO of SapiensBio

Source:

Alzheimer Research UK

.